Anatara is nearing conclusion of a process of due diligence and negotiation with many of the world's leading animal health companies. Anatara's objective being to partner with a company or companies to register Detach(R) in key overseas markets.
Notice is hereby given that an Extraordinary General Meeting (EGM) of iQX Limited (NSX:IQX) will be held at ParkRoyal Darling Harbour at 10.00am (AEST) on Tuesday 14 July 2020.
iQX Limited (iQX Ltd) (NSX:IQX) would like to announce a collaboration agreement between the Wyss Institute for Biologically Inspired Engineering, Harvard University, and Life Science Biosensor Diagnostics Pty Ltd (LSBD), in which iQX Ltd holds a 19% equity position.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced that non-executive director Dr Glen Richards has resigned to allow him to focus on his other commitments.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced that it has received notification that Kyocera Corporation (TYO:6971) has completed its due diligence process on its lead stem cell platform technology Progenza for treatment of Knee Osteoarthritis (Progenza OA).
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today released its quarterly cashflow report and review of operational activities for the period ending 31 March 2020.
Anatara Lifesciences Ltd (ASX:ANR) is pleased to release its Appendix 4C for the quarter ending 31st March 2020. The Company's cash plus term deposits at the end of the quarter stood at $3.3m.
